Abstract
This report provides a complete insight to the technology, companies and
research institutions that are driving this high-growth and promising sector.
Providing...
- A review of nanomedicine and its role in the anticancer market
- An assessment of the main areas in which it can be applied
- Analysis of 6 current products employing nanotechnology
- A review of the work of 30 companies with products in the pipeline
- A thorough look at current research being conducted at over 30
institutions worldwide
This rapidly-expanding and topical area of research promises better
clinical outcomes, targeted therapies and profits for the industry. But what
is the current state of play and where are the real opportunities emerging?
Diagnosing, treating and tracking the progress of therapies for each type of
cancer that exists has long been a dream among oncologists, and one that has
recently grown closer with developments in genomics, proteomics and cell
biology.
Now, a revolution in nanotechnology is pushing personalised cancer treatment
closer than ever before. Future techniques in medical diagnosis and treatment
have often been the subject of science fiction and fantasy.
What was once literary fantasy is now closer to becoming reality. Nature
already operates at the nanoscale and today we are acquiring an increasingly
profound understanding of natural processes at this scale, enabled by a new
generation of scientific instruments.
To provide industry executives with a comprehensive and easy to read
evaluation of this fast growing area, Espicom Business Intelligence has
published this detailed new 125-page report. Covering every aspect of the
subject from current research to applications, products, future pipeline and
ongoing research, the report provides a complete review of nanomedicine and
its growing importance in the cancer field.
This report provides a complete insight to the technology, companies and
research institutions that are driving this high-growth and promising sector.
|